Relation of benzodiazepine use to the risk of selected cancers: Breast, large bowel, malignant melanoma, lung, endometrium, ovary, non-hodgkin's lymphoma, testis, hodgkin's disease, thyroid, and liver Journal Article


Authors: Rosenberg, L.; Palmer, J. R.; Zauber, A. G.; Warshauer, M. E.; Strom, B. L.; Hariap, S.; Shapiro, S.
Article Title: Relation of benzodiazepine use to the risk of selected cancers: Breast, large bowel, malignant melanoma, lung, endometrium, ovary, non-hodgkin's lymphoma, testis, hodgkin's disease, thyroid, and liver
Abstract: Some animal data have raised the possibility that benzodiazepines influence the risk of selected cancers. With data collected in 1977-1991 in a US hospital-based study, the authors assessed the relation of benzodiazepine use to the risk of 11 cancers: breast (6,056 patients), large bowel (2,203), malignant melanoma (1,457), lung (1,365), endometrium (812), ovary (767), non-Hodgkin's lymphoma (382), testis (314), Hodgkin's disease (299), thyroid (111), and liver (37). Cases were compared with cancer controls (3,777 patients with other cancers) and noncancer controls (1,919 patients admitted for acute nonmalignant disorders). Relative risks were estimated for benzodiazepine use at least 4 days a week for at least 1 month, initiated at least 2 years before admission (sustained use) by multiple logistic regression with control for confounding factors. Results derived with noncancer controls were similar to those derived with cancer controls. For sustained benzodiazepine use relative to no use, relative risk estimates for all 11 cancers were compatible with 1.0 at the 0.05 level of significance. Relative risk estimates for durations of at least 5 years were also compatible with 1.0, with the exceptions of an increased estimate, of borderline statistical significance, for endometrial cancer, and a decreased estimate for ovarian cancer. Relative risk estimates both for sustained use that continued into the 2-year period before admission and for sustained use that ended up to ≥ 10 years previously were compatible with 1.0, suggesting a lack of tumor promotion and no increase in the risk after a latent interval. Results were also null for diazepam, chlordiazepoxide, and other benzodiazepines considered separately. The results suggest absence of association between benzodiazepine use and the cancers considered, with the evidence stronger for the cancers with larger numbers of subjects. The similarity of results derived with cancer and noncancer controls suggests that benzodiazepines do not influence the risk of cancer as a whole. © 1995 by The Johns Hopkins University School of Hygiene and Public Health.
Keywords: adolescent; adult; controlled study; aged; major clinical study; case-control studies; cancer risk; liver neoplasms; endometrium carcinoma; neoplasms; melanoma; logistic models; lung neoplasms; colonic neoplasms; breast neoplasms; hodgkin disease; risk; liver carcinoma; genital neoplasms, female; nonhodgkin lymphoma; lymphoma, non-hodgkin; breast carcinoma; ovary carcinoma; testicular neoplasms; benzodiazepine derivative; lung carcinoma; thyroid carcinoma; thyroid neoplasms; colon carcinoma; middle age; testis carcinoma; diazepam; benzodiazepines; human; male; female; article; chlordiazepoxide; support, non-u.s. gov't; support, u.s. gov't, p.h.s.
Journal Title: American Journal of Epidemiology
Volume: 141
Issue: 12
ISSN: 0002-9262
Publisher: Oxford University Press  
Date Published: 1995-06-15
Start Page: 1153
End Page: 1160
Language: English
DOI: 10.1093/oxfordjournals.aje.a117388
PUBMED: 7771453
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 28 August 2018 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Ann G Zauber
    314 Zauber